Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Gynaecological cancers 2

807O - Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)


21 Sep 2020


Proffered Paper - Gynaecological cancers 2


Kohei Omatsu


Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276


K. Omatsu1, J. Hamanishi2, N. Katsumata3, S. Nishio4, K. Sawada5, S. Takeuchi6, D. Aoki7, K. Fujiwara8, T. Sugiyama9, I. Konishi10

Author affiliations

  • 1 Gynecologic Oncology Department, The Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Department Of Gynecology And Obstetrics, Kyoto University Graduate School of Medicine, 606-8507 - Kyoto/JP
  • 3 Department Of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kanagawa/JP
  • 4 Department Of Obstetrics And Gynecology, Kurume University School of Medicine, 830-0011 - Fukuoka/JP
  • 5 Department Of Obstetrics And Gynecology, Osaka University Graduate School of Medicine, Osaka/JP
  • 6 Department Of Gynecology, Kobe Tokushukai Hospital, Kobe/JP
  • 7 Department Of Obstetrics And Gynecology, Keio University School of Medicine, Tokyo/JP
  • 8 Department Of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama/JP
  • 9 Department Of Obstetrics And Gynecology, St. Mary's Hospital, Fukuoka/JP
  • 10 Honorary Director, Kyoto Medical Center, Kyoto/JP


Login to access the resources on OncologyPRO.

Abstract 807O


Nivolumab, a human anti-programmed death-1 (PD-1) receptor monoclonal antibody, is effective against some cancers. A phase II trial has supported the efficacy of nivolumab in platinum-resistant ovarian cancer, but a randomized trial is required to confirm its efficacy. This multicenter, open-label, randomized, phase III study investigated the efficacy and safety of nivolumab vs gemcitabine or pegylated liposomal doxorubicin (GEM/PLD) in platinum-resistant ovarian cancer.


Patients aged ≥20 years with platinum-resistant (advanced or recurrent) ovarian cancer and no prior GEM/PLD treatment were randomized (1:1) to nivolumab (240 mg intravenously [IV], every 2 weeks) or GEM/PLD (GEM 1000 mg/m2 IV for 30 minutes on days 1, 8, and 15, then every 4 weeks; or PLD 50 mg/m2 IV every 4 weeks) after stratifying for histological type (clear cell carcinoma vs others) and number of prior chemotherapy regimens after diagnosis of resistance (0 or 1). Treatment continued until disease progression or unacceptable toxicity. Tumor was assessed every 8 weeks through week 48, then every 12 weeks. Primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and safety.


Of 316 patients randomized, 77.8% had ≥2 prior chemotherapies and 14.2% had ECOG PS score of 1. Median OS was 10.12 (95% confidence interval [CI], 8.34-14.09) months with nivolumab (n=157) and 12.09 (95% CI, 9.26-15.34) months with GEM/PLD (n=159), with no statistically significant difference between the groups (hazard ratio [HR] 1.03, 95% CI, 0.80-1.32; P=0.808). Median PFS was 2.04 (95% CI, 1.91-2.20) months with nivolumab and 3.84 (95% CI, 3.58-4.17) months with GEM/PLD (HR 1.46; 95% CI, 1.15-1.85; P=0.002). The rate of treatment-related grade 3/4 adverse events (AEs) was 22.4% with nivolumab and 68.4% with GEM/PLD; the major AEs (all grades) with nivolumab were diarrhea (15.4%), nausea, pruritus and rash (12.2% each). There was no difference in the toxicity profile of nivolumab from that previously reported.


Nivolumab did not improve OS compared with GEM/PLD in patients with platinum-resistant ovarian cancer.

Clinical trial identification


Editorial acknowledgement

Medical writing assistance was provided by Hana Nomura, BPharm, of ProScribe - Envision Pharma Group and was funded by Ono Pharmaceutical Co., Ltd.

Legal entity responsible for the study

Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company.


Ono Pharmaceutical Co., Ltd.


J. Hamanishi: Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (self): Merck Sharp & Dohme; Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (institution): Sumitomo Dainippon Pharma. N. Katsumata: Advisory/Consultancy: AbbVie. D. Aoki: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca K.K.; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical; Honoraria (self), Advisory/Consultancy: Merck Sharpe Dohme; Advisory/Consultancy, Research grant/Funding (institution): Takeda Pharmaceutical; Advisory/Consultancy: Zeria Pharmaceutical. K. Fujiwara: Honoraria (self): Bayer; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Daiichi Sankyo; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Nippon Kayaku; Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Zeria Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Kaken Pharmaceutical; Research grant/Funding (institution): Oncotherapeutics; Research grant/Funding (institution): ImmunoGen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings